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Transforming growth factor betaThe Jagged/Notch pathway has been implicated in TGFβ1 responses in epithelial cells in diabetic nephropathy
and other ﬁbrotic conditions in vivo. Here, we identify that Jagged/Notch signalling is required for a subset of
TGFβ1-stimulated gene responses in human kidney epithelial cells in vitro. TGFβ1 treatment of HK-2 and
RPTEC cells for 24 h increased Jagged1 (a Notch ligand) and Hes1 (a Notch target) mRNA. This response was
inhibited by co-incubation with Compound E, an inhibitor of γ-secretase (GSI), an enzyme required for Notch
receptor cleavage and transcription regulation. In both cell types, TGFβ1-responsive genes associated with
epithelial–mesenchymal transition such as E-cadherin and vimentin were also affected by γ-secretase
inhibition, but other TGFβ1 targets such as connective tissue growth factor (CTGF) and thrombospondin-1
(THBS1) were not. TGFβ1-induced changes in Jagged1 expression preceded EMT-associated gene changes,
and co-incubation with GSI altered TGFβ1-induced changes in cell shape and cytoskeleton. Transfection of
cells with the activated, cleaved form of Notch (NICD) triggered decreased expression of E-cadherin in the
absence of TGFβ1, but did not affect α-smooth muscle actin expression, suggesting differential requirements
for Notch signalling within the TGFβ1-responsive gene subset. Increased Jagged1 expression upon TGFβ1
exposure required Smad3 signalling, and was also regulated by PI3K and ERK. These data suggest that Jagged/
Notch signalling is required for a subset of TGFβ1-responsive genes, and that complex signalling pathways are
involved in the crosstalk between TGFβ1 and Notch cascades in kidney epithelia.lar Science, Queen's University
d, Belfast BT12 6BA, Northern
2699.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
TGFβ1 is the primary cytokine mediator of ﬁbrotic kidney disease
[1,2]. Canonical Smad signalling in response to TGFβ1 involves
phosphorylation of Smad2/3 which then dimerise with Smad4,
translocate to the nucleus and bind to speciﬁc promoters to regulate
the transcription of TGFβ-responsive genes [3]. Many other signal
transduction pathways have been implicated in TGFβ-induced ﬁbrosis
in kidney and other organs, including PI3K/Akt, p38MAPK, NFκB and
RhoA [4–8]. In kidney, TGFβ1 has been reported to induce epithelial–
mesenchymal transition leading to increased myoﬁbroblast accumu-
lation and scarring of kidney [9,10]. The process of EMT is
characterised by disassembly of epithelial cell adherens junctions,
changes in cell shape, degradation and invasion of the basement
membrane and myoﬁbroblast migration [11]. In vitro, EMT can betracked by detecting reduced E-cadherin and ZO-1 expression in the
adherens and tight junctions, together with increased expression of
α-smooth muscle actin and vimentin myoﬁbroblast markers [12,13].
Although a large volume of data supports a role for TGFβ1-induced
EMT in kidney disease in vivo [14–16], recent data from Dufﬁeld and
colleagues has suggested that alternative cell types such as pericytes
may also contribute tomyoﬁbroblast formation in kidney ﬁbrosis [17].
Notch proteins are cell surface transmembrane receptors that
control multiple developmental processes in metazoan development
[18,19]. Notch signalling involves intercellular binding of Notch
receptors with Jagged/Delta ligands on adjacent cells [19,20].
Activation of Notch receptor triggers the release of Notch intracellular
domain (NCID) via the action of the γ-secretase protease, amember of
the presenillin family [19]. Released NICD then translocates to the
nucleus where it interacts with the CSL family of transcription factors
(CBF-1/RBP-Jk, Su (h) and LAG-1) [21]. Notch/CSL both represses and
activates transcription via the recruitment of chromatin remodelling
complexes containing either histone deacetylases or histone acetylase
proteins [18]. Notch receptor cleavage (via the action of γ-secretase)
is required for nephrogenesis and normal podocytes/proximal tubule
formation in the developing mouse kidney [22,23].
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and 2, Hes1 and Hey1 have been identiﬁed as TGFβ1-responsive genes
in diverse epithelia [24–26]. Zavadil and colleagues identiﬁed that
inhibition of Jagged/Notch signalling using RNAi blocked TGFβ1-
induced EMT progression in keratinocytes [27], suggesting a potential
role for Notch signalling in ﬁbrosis. In vivo, elevated Jagged/Notch
signalling has been identiﬁed in a range of different ﬁbrotic diseases of
the kidney, liver and lung [25,26,28–30]. Levels of Jagged1 and Hes1 are
also elevated in human diabetic nephropathy [26]. In transgenic mice,
overexpression of the Notch intracellular domain (NICD) in podocytes
triggers glomerulosclerosis [31,32]. Therapeutic interventions using
inhibitors of Notch receptor cleavage (γ-secretase inhibitors, GSI) and
soluble Notch ligands alleviate renal failure in mice, suggesting that
pharmacological targeting ofNotchmaybe of beneﬁt in the treatmentof
human kidney disease [31–33].
In the present study, we interrogate the signalling pathways
triggered by TGFβ1 that regulate Jagged/Notch and EMT-associated
gene expression in human kidney proximal tubule epithelial cells. We
identify that Smad3, PI3K and ERK signalling are involved in TGFβ1-
mediated stimulation of Jagged1 gene expression. Additionally, our
data suggests that a subset of TGFβ1-regulated genes require Notch
signalling, data which advances our understanding of the role of
Notch signalling in the kidney.
2. Materials and methods
2.1. Cell culture and transfection
Human proximal tubule epithelial cells (HK-2) were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM-F12, Sigma) supple-
mented with 10% (vol/vol) fetal calf serum (GIBCO), 2% (v/v)
penicillin/streptomycin, 1% (v/v) L-glutamine, EGF (10 μg/ml), tri-
iodothronine (40 ng/ml), hydrocortisone (36 ng/μl), and 1% ITS
(Sigma) at 37 °C in 95% air–5% CO2. Primary human renal proximal
tubule epithelial cells (RPTEC) were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM-F12) supplemented with 10% (v/v) fetal calf
serum, 2% penicillin/streptomycin, 1% L-glutamine, EGF (10 μg/ml)
and 1% ITS, at 37 °C in 95% air and 5% CO2. Prior to exposure to TGFβ
minus/plus GSI, cells were cultured in minimum starvation media
containing only antibiotics and L-glutamine.
For TGFβ1 treatments, cells were cultured in six-well plates and
treated with vehicle (PBS) or 5 ng/ml recombinant human TGFβ1
(PromoCell) for 24 h. Pharmacological inhibitors LY294002, PD98059,
SB431542 and SIS3 were added at 1 μM concentration 60 min prior to
treatment with TGFβ1. The γ-secretase inhibitor (Compound E,
Alexis) was added together with TGFβ1 at either 0.03 nM, 0.3 nM,
3 nM or 30 nM for 24 h.
For HK-2 transfections, cells were cultured in six-well plates and
transfected at 70% conﬂuency. For transfections, 1 μg of empty vector,
1 μg pCMX-Notch IC and 1 μg RPMS-1 were used. Transfections were
carried out using OptiMeM (GIBCO) and Fugene 6 Transfection
Reagent (Roche) at a 3:1 Fugene:DNA ratio. Twenty four hours after
transfection, the medium was replaced and cells were exposed to
TGFβ1 for a further 24 h.
2.2. TaqMan PCR
RNA extraction was carried out using Trizol reagent (BioSciences)
according to the manufacturer's protocol. RNA concentration was
determined using a Nanodrop spectrophotometer and cDNA was
synthesised using Superscript II Reverse Transcriptase (Invitrogen).
TaqMan PCR was carried out using the following human real-time
probes (Applied Biosystems): E-cadherin (Hs00170423_m1), Vimentin
(Hs00185584_m1), CTGF (Hs00170014_m1), THBS-1 (Hs00170236_
m1), Jagged1 (Hs00164982_m1) and Hes1 (Hs00172878_m1). Gener-
ated products were then analysed on an ABI Prism 7700 sequencedetection system. Data were calculated using the ΔΔCt method and
normalised to 18S levels.
2.3. Protein harvesting and Western blotting
For protein analysis, cells were harvested on ice in RIPA buffer
containing 50 mM Tris–HCl, pH 7.4, 1% (vol/vol) Nonidet P-40, 0.25%
(wt/vol) sodium deoxycholate, 150 mM NaCl and 1 mM EDTA,
supplemented with 1× protease inhibitor cocktail (Sigma), 2 μM
microcystin (Alexis Biochemicals), 10 μM Benzamidine, 1 mM NaF,
40 mM β-glycerophosphate, 1 mM sodium vanadate and fresh 1 mM
phenylmethylsulfonyl ﬂuoride. Cells were incubated on ice for
20 min, vortexing every 5 min. Cells were then centrifuged at
14,000 rpm at 4 °C for 20 min to remove cell debris. Protein
concentration was determined using Bradford reagent (Bio-Rad)
and read on a plate reader using SoftPro Max software at an
absorbance of 595 nm. Proteins were resolved using either 7.5% or
12% SDS-PAGE and then transferred to a polyvinylidene diﬂouride
membrane (PVDF, Immobilon P, Millipore) at 110 V for 75 min.
Membranes were blocked with 3% (wt/vol) milk (made up in TBS-T
[10 mM Tris–HCl pH 7.4, 150 mM NaCl and 0.1% Tween 20]) for
60 min at RT. Membranes were then incubated with the following
antibodies: polyclonal Jagged1 (1:1000, Santa Cruz), monoclonal E-
Cadherin (1:1000, BD Transduction Laboratories), monoclonalα-SMA
(1:1000, Sigma), and monoclonal β-actin (1:10,000, Sigma) diluted in
3%milk overnight at 4 °C. The following daymembranes werewashed
with TBS-T for three 10-min washes, before incubation with either
HRP-coupled anti-rabbit (Cell Signaling) or anti-mouse (Cell Signal-
ing) secondary antibodies at 1:2000 dilution in 3% milk for 1 h at RT.
Membranes were washed with TBS-T for three 10-min washes.
Western Blotting Luminol Reagent (Santa Cruz Biotechnology) was
then used, along with an X-ray ﬁlm, to reveal the reactive bands.
2.4. Immunoﬂuorescence
HK-2 cells plated on 8-well chamber slides (Nunc) were treated
with TGFβ1 and γ-secretase inhibitor Compound E added as
previously described. After 24 h, the culture medium was aspirated
and the slides were washed with PBS and ﬁxed with 3.7%
paraformaldehyde. Cells were permeabilised with 0.1% Triton-X 100
(Sigma) and blocked with 5% goat serum (Sigma) for 1 h. The slides
were incubated overnight with primary antibodies to E-cadherin
(Abcam), α-smooth muscle actin (Sigma), each at a concentration
of 1:100 in 5% goat serum. The next day, slides were washed with
PBS and incubated with secondary anti-mouse/rabbit Texas Red
conjugated antibody (Molecular Probes) at a concentration of 1:200 in
5% goat serum. Slides were washed in PBS and incubated with 1:200
Alexa Fluor 488 phalloidin (Invitrogen) in PBS for 30 min, followed
by Hoechst dye (Invitrogen), at 1:1000 in PBS for 2 min. Two drops
(10–15 μl) of ProLong Antifade Gold (Invitrogen) was added to each
well, prior to placing coverslips. Slides were visualised with a Zeiss
AxioVision Imager M2 upright ﬂuorescence microscope using AxioVi-
sion 4.8 software. Multi-dimensional images were acquired from
replicate slide wells and representative images are presented.
3. Results
Previous data from our laboratory and others identiﬁed upregula-
tion of Jagged1 gene expression as a feature of TGFβ-mediated renal
ﬁbrosis and diabetic kidney disease [25–27]. Global gene expression
analysis using Affymetrix gene arrays identiﬁed Jagged1 as the most
signiﬁcantly upregulated gene in response to 24 h TGFβ1 treatment in
HK-2 cells [26]. To assess the sensitivity of Jagged/Notch-mediated
gene expression, human kidney epithelial cells (HK-2) were incubat-
ed with a range of increasing TGFβ1 concentrations for 24 h. Dose-
dependent changes in the expression of genes associated with TGFβ1
1388 K.C. Nyhan et al. / Biochimica et Biophysica Acta 1803 (2010) 1386–1395induced renal ﬁbrosis were then compared to alterations in Jagged/
Notch pathway genes. Increasing concentrations of TGFβ1-induced a
decrease in the levels of E-cadherin mRNA, and an increase in the
amount of vimentin mRNA, changes previously identiﬁed as integral
to TGFβ-induced epithelial–mesenchymal transition in vitro (Fig. 1
top panels, [9]). Levels of connective tissue growth factor (CTGF) and
thrombospondin-1 (THBS1) also increased in a concentration-
dependent manner (Fig. 1 middle panels). Jagged1 mRNA, as well as
the Jagged/Notch target gene Hes1 also increased in HK-2 cells
treated with TGFβ1 (Fig. 1 bottom panels). Marked differences in the
responsiveness of each gene to TGFβ1 were detected, with 2-fold
increases in vimentin expression and 8–10-fold increases in CTGF,
THBS1 and Jagged1 mRNA detected. The EC50 of TGFβ1 for each
individual gene analysed was broadly similar, with values between
2.1 and 4.2 ng/ml calculated (Fig. 1). Based on these data, all further
experiments were performed using 5 ng/ml TGFβ1 for 24 h to ensure
comparable responses.
Activation of Jagged/Notch signalling requires cleavage of the
Notch receptor by γ-secretase, liberating a Notch receptor intracel-
lular fragment (NICD)which translocates to the nucleus and regulates
gene transcription [19]. To assess whether Notch receptor processing
was required for TGFβ1-induced changes in Jagged1 and Hes1, HK-2
cells were incubated with increasing concentrations of a γ-secretase
inhibitor (GSI). The robust increases in Jagged1 and Hes1 target gene0
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Fig. 1. TGFβ1 induces concentration-dependent gene responses in HK-2 cells. HK-2 cells wer
Control cells (empty bars) were treated with vehicle. Cells were harvested for RNA and chang
thrombospondin-1 (THBS-1), Jagged1 (Jag1) and hairy and enhancer of split 1 (Hes1) w
experiments were carried out in triplicate. Statistical analysis was carried out using one-way
test. Statistical differences shown are compared to control vehicle group (0 ng/ml TGFβ1).levels triggered by TGFβ were inhibited by GSI in a concentration-
dependent manner, with IC50 values of 0.76 and 2.9 nM respectively
(Fig. 2A, B). Inhibition of TGFβ1-induced Jagged1 by GSI was also
observed at the protein level (Fig. 2C, D). GSI-mediated inhibition of
Jagged1 and Hes1 RNA induction in the absence of TGFβ1 suggested
that in Jagged/Notch signalling an autocrine signalling loop may exist
to regulate target gene expression in these cells (Suppl. Fig. 1). Similar
induction of Jagged1 and sensitivity to GSI were seen in primary renal
proximal tubule epithelial cells (RPTEC) treated with TGFβ1 (Suppl.
Fig. 2). Thus, TGFβ-mediated activation of Jagged1 pathway gene
expression requires Jagged/Notch receptor activation and cleavage in
two independent kidney epithelial cell lines.
Additional TGFβ1-mediated gene expression changes in HK-2 cells
were then assessed in HK-2 cells minus/plus GSI. Interestingly,
differential sensitivity to GSI was displayed by TGFβ1-regulated
genes, where increasing concentrations of GSI inhibited TGFβ1-
mediated changes in E-cadherin, α-SMA and vimentin mRNA
(Fig. 3A–C). Lower concentrations of GSI appeared to have a bigger
effect on α-SMA mRNA levels (Fig. 3B). In contrast, γ-secretase
inhibition had a minimal effect on TGFβ1-induced increases in CTGF
and THBS1 gene expression (Fig. 3D, E). TGFβ1-stimulated expression
of Grem1, a gene implicated in renal disease [34,35], was also
insensitive to GSI up to 30 nM (Fig. 3F). Again, similar trends were
detected in RPTEC cells, with TGFβ1-induced changes in E-cadherin0
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Fig. 2. TGFβ1-stimulation of Jagged1 expression requires Notch receptor cleavage. A, B. HK-2 cells were treated with vehicle (empty bars) or 5 ng/ml TGFβ1 (ﬁlled bars) for 24 h in
the presence of γ-secretase inhibitor (GSI) at 0.03, 0.3, 3 or 30 nM (striped bars). DMSO was included in the vehicle and TGFβ1-treated cells as a negative control. Cells were
harvested for RNA and quantitative TaqMan PCR was carried out. mRNA levels were normalised to control 18S, and experiments were carried out in triplicate. Statistical analysis was
carried out using one-way ANOVA with post hoc Tukey–Kramer multiple comparison test. Statistical differences shown are compared to control group unless otherwise indicated.
**pb0.01, ***pb0.001. IC50 values were calculated using Prism software. C. HK-2 cells were treated with 5 ng/ml TGFβ1 for 24 h in the absence or presence of GSI at 0.3 nM or 3 nM
concentrations. DMSO was used as a negative control. Protein lysates were extracted and separated by SDS-PAGE on a 7.5% gel, and probed with the Jagged1 antibody. β-Actin was
used as a loading control. Experiments were carried out in duplicate and repeated n=3 times. D. Densitometry was carried out using Scion Image and Jagged1 band intensity was
normalized to β-actin. Statistical analysis was carried out using one-way ANOVA with post hoc Tukey–Kramer multiple comparison test. Values for TGFβ1-treated cells were
compared to vehicle control (empty bar), and values for TGFβ1+GSI (striped bars) were compared to TGFβ1+DMSO (ﬁlled bar). **pb0.01, ***pb0.001.
Fig. 3. Notch receptor cleavage is required for a subset of TGFβ1 responsive genes. HK-2 cells were treated with vehicle (empty bars) or 5 ng/ml TGFβ1 for 24 h minus/plus GSI at
0.03, 0.3, 3 or 30 nM concentrations (striped bars), with DMSO as a negative control (ﬁlled bars). Cells were harvested for RNA and changes in the levels of the indicated genes were
analysed. Levels of each gene were normalised to control 18S, and experiments were carried out in triplicate. Statistical analysis was carried out using one-way ANOVAwith post hoc
Tukey–Kramer multiple comparison test. Statistical differences shown are compared to vehicle control group, unless otherwise indicated (Fig. 3B). *pb0.05, **pb0.01, ***pb0.001.
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1390 K.C. Nyhan et al. / Biochimica et Biophysica Acta 1803 (2010) 1386–1395and α-SMA inhibited by GSI, with no signiﬁcant inhibition of CTGF
RNA levels seen (Suppl. Fig. 3A–C). GSI incubation caused little or no
inhibition of baseline RNA levels for all four genes tested without
TGFβ1, suggesting that the GSI effect is speciﬁc for TGFβ1-mediated
gene induction, rather than baseline transcription per se (Suppl.
Fig. 1C–F). Signiﬁcantly, upregulation of Jagged1 and Hes1 mRNA at
the 12 h time-point in TGFβ1-treated HK-2 cells preceded changes in
EMT-associated gene targets such as E-cadherin and α-SMA (Fig. 4).
These data suggest that Notch receptor cleavage and pathway
activation are required for a subset of TGFβ1-mediated gene
expression changes in HK-2 epithelial cells.
To examine the phenotypic consequence of Jagged/Notch inhibi-
tion on TGFβ1-induced EMT, HK-2 cells were stained with antibodies
against α-SMA and E-cadherin, both well established protein markers
of EMT [13,15]. TGFβ1 treatment of HK-2 epithelial cells triggered the
formation of an intermediate cell phenotype, with increased α-SMA,
loss of E-cadherin as well as actin rearrangement and increased stress
ﬁbres visible (Fig. 5A, B, left panels). Co-incubation of cells with
increasing concentrations of GSI prevented TGFβ1-induced changes in
α-SMA expression and re-established punctuate E-cadherin staining
at the nucleus and cell–cell junctions (Fig. 5A, B), and also reverted the
EMT-like changes in actin cytoskeleton (Fig. 5A, 30 nM, 20×). These
data suggest that previously observed effects of Jagged/Notch
signalling on TGFβ1-induced mRNA changes are also present at the
protein level, regulating cell phenotype changes associated with
TGFβ1-induced EMT.
Notch1 is one of over 60 reported substrates of γ-secretase in
cells [19]. To more speciﬁcally address whether cleavage of Notch1
receptor affects TGFβ1-regulated genes, a “pre-cleaved” version of
the Notch receptor (NICD) and a negative regulator of NICD/CBF-1
transcription (RPMS1 [21,36]) were utilised (Fig. 6). Transfection of
HK-2 cells with NICD increased both Jagged1 and α-SMA protein
expression in the absence and presence of TGFβ1 (Fig. 6A–C).0
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Fig. 4. Jagged1 induction precedes EMT-associated gene changes in kidney epithelial cells. H
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using one-way ANOVA with post hoc Tukey–Kramer multiple comparison test. Experiments
vehicle control for each gene. *pb0.05, **pb0.01.TGFβ1-induced mRNA levels for Jag1 and α-SMA were also
increased in NICD-transfected cells (Suppl. Fig. 4). NICD had little
or no effect on E-cadherin protein or RNA expression, suggesting
that Notch receptor cleavage is necessary, but not sufﬁcient for E-
cadherin downregulation (Fig. 6A, D and Suppl. Fig. 4C). Transfec-
tion of the RPMS1 inhibitor of Notch1-mediated gene transcription
only modestly reduced TGFβ1-induced increases in Jagged1 and α-
SMA, with little effect on E-cadherin expression levels (Fig. 6).
These changes were also reﬂected at the mRNA level (Suppl. Fig. 4).
These data suggest that diverse TGFβ1 gene targets display different
modes of regulation by elements of the Jagged1/Notch signalling
cascade.
Canonical TGFβ-pathway signalling involves TGFβ type II/I
receptor-mediated phosphorylation of Smad2/3, which then dimerise
with Smad4 and translocate to the nucleus to drive gene transcription
[3]. Other signalling pathways such as the PI3K/Akt and MAPK
pathways are also activated by TGFβ in different cells [4–6]. To
examine whether canonical Smad signalling was involved in TGFβ1-
mediated Jagged1 upregulation, HK-2 cells were incubated with both
a TGFβ1 receptor Ser/Thr kinase antagonist (SB431542) and a speciﬁc
Smad3 inhibitor (SIS3, [37]). Induction of Jagged1 protein by TGFβ1
was abolished by the pretreatment of cells with both SB431542 and
SIS3 (Fig. 7A, B). TGFβ1-induced phosphorylation of Smad3 was also
signiﬁcantly reduced by both of these inhibitors (Fig, 7A, B),
suggesting that activation of Smad signalling is required for Jagged1
induction in response to TGFβ1. Inhibitors of non-canonical TGFβ
signalling pathways such as PI3K/Akt (LY294002) and ERK
(PD98059) also inhibited Jagged1 upregulation in response to
TGFβ1 (Fig. 7C, D). However, this inhibition was less dramatic than
that detected with the TGFβ1 receptor/Smad3 inhibitors (Fig. 7A, B).
These data suggest that both canonical Smad signalling and non-
canonical PI3K/Akt and ERK signalling contribute to TGFβ1-induced
upregulation of Jagged1 in HK-2 epithelial cells.0
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Changes in the Jagged/Notch signalling pathway have previously
been implicated in diabetic nephropathy and other ﬁbrotic conditionsof the kidney [25,27,31,32]. Using both a chemical inhibitor and cDNA
transfection approach, we demonstrate that cleavage and activation of
the Notch receptor is required for a subset of TGFβ1 gene responses in
two distinct human kidney tubule epithelial cells (HK-2 and RPTEC).
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separated by 7.5% SDS-PAGE, and probed with antibodies against Jagged1, α-SMA, E-cadherin, HA afﬁnity tag and FLAG afﬁnity tag. β-Actin was used as a loading control.
Experiments were carried out n=3 times. B–D. Densitometry was carried using Scion Image. Jagged1, E-cadherin and α-SMA band intensity was normalized to β-actin. Statistical
analysis was carried out using one-way ANOVA with post hoc Tukey–Kramer multiple comparison test. *pb0.05.
Fig. 7. Both canonical and non-canonical TGFβ1 signalling pathways regulate Jagged1 expression. HK-2 cells were treated with vehicle (empty bars) or 5 ng/ml TGFβ1 (ﬁlled bars)
for 24 h. Cells were co-incubated with either the TGFβ1 receptor inhibitor SB431542 or the Smad3 inhibitor SIS3 (A, B), or the PI3K inhibitor LY294002 or the MAPK inhibitor
PD98059 (C, D) at 10 μM concentration, added 1 h before TGFβ1. DMSO was added to both vehicle and TGFβ1-treated cells as a negative control. Protein lysates were separated by
7.5% SDS-PAGE, and probed with Jagged1 or phospho-Smad3 antibody. β-Actin was used as a loading control. Experiments were carried out n=3 times. B, D. Densitometry was
carried out using Scion Image and Jagged1 band intensity was normalized to β-actin. Statistical analysis was carried out using one-way ANOVAwith post hoc Tukey–Kramer multiple
comparison test. *pb0.05, **pb0.01, ***pb0.001.
1392 K.C. Nyhan et al. / Biochimica et Biophysica Acta 1803 (2010) 1386–1395
1393K.C. Nyhan et al. / Biochimica et Biophysica Acta 1803 (2010) 1386–1395Both Jagged1 and the Jagged/Notch target gene Hes1 are exquisitely
sensitive to γ-secretase inhibition, which prevents Notch receptor
cleavage and activation. Upregulation of Jagged1 and Hes1 mRNA
precede EMT-associated gene changes in response to TGFβ1 in HK2
cells. TGFβ1 induction of Jagged1 requires both canonical Smad3
phosphorylation and non-canonical PI3K/ERK activation. These data
suggest that TGFβ1-mediated regulation of the Jagged/Notch signal-
ling pathway in epithelial cells is a complex process that may involve
autoregulation at the transcriptional level. A model summarising our
data is presented in Fig. 8.
Intercellular interactions between Jagged/Delta and Notch2 [38] on
adjacent cells play a key role in renal development, speciﬁcally in
podocyte and proximal tubule formation [22,23,39]. A role for this
signalling pathway has also been identiﬁed in autoimmunity, liver
ﬁbrosis and pancreatic cancer [28,29,31,32,40,41]. Jagged1 was initially
identiﬁed as a TGFβ1 target gene in keratinocytes [24] and HK-2 kidney
epithelial cells [25]. Levels ofmultiple componentsof theNotchpathway
including Jagged1, proteolytically cleaved activated Notch receptor
(NICD) and Hes1 were elevated in both animal models of diabetic
nephropathy and human patient biopsies in both glomerular [31] and
tubular kidney compartments [26]. In our hands, Jagged1 was the
highest upregulated mRNA in human kidney proximal tubule epithelialSmad
2/3
PI3K/
AktERK
TGFβ1 receptor
JaggedE-cadherin
α-SMA
A
γ
NICD
Jagged1 (
Notch
CSL CSL
Fig. 8. Proposed mechanism of Notch-mediated regulation of TGFβ1 gene responses in kidne
including canonical Smad2/3 phosphorylation, PI3K/Akt and MAPK. Intercellular signalling
protease mediated cleavage of the extracellular domain of Notch, and intracellular liberation
the CSL transcriptional complex (containing the RBPj transcription factor) to regulate gene
receptor cleavage for transcriptional regulation. Other genes such as thrombospondin-1 (TH
inﬂuence. Further complexity of regulation may exist where NICD is sufﬁcient to activate TGF
arrow). Crosstalk between the two pathways is indicated by the double-headed arrow.cells (HK-2) treated with TGFβ1 for 24 h [26], with Hes1 upregulation
also observed under these conditions (Fig. 1). Our data identiﬁed that
TGFβ1-induced changes in Jagged1andHes1were sensitive to inhibition
of Notch receptor cleavage with γ-secretase inhibitor in both HK-2 and
RPTEC cell lines (GSI, Fig. 2; Suppl. Figs. 2, 3). This is in contrast to data
fromkeratinocytes,whereGSI incubation did not inhibit TGFβ1-induced
upregulation of Hey1, a Notch target related to Hes1 [27]. Differences in
epithelial cell lines (kidney epithelial cells versus keratinocytes) and
distinct GSI inhibitors (Compound E versus GSI-X) usedmay explain the
disparity in these data. The earlier induction of Jagged1 at 12 h in
response to TGFβ1 versus 24 h for EMT-associated genes such asα-SMA
(Fig. 4) supports the idea that activation of Jagged/Notch signalling
impinges on TGFβ1-induced EMT-like changes in kidney epithelial cells.
Overexpression of the transcriptionally active Notch intracellular
domain (NICD) also drove Jagged1 expression in the absence and
presence of TGFβ1 (Fig. 6A, B). These data suggest that TGFβ1 induction
of Jagged1 ligand andHes1 target gene expression requires activation of
the Jagged/Notch signalling cascade in kidney epithelial cells, which
may form part of an autoregulatory loop limiting Jagged1/Hes1
expression to cells also expressing activated Notch receptor.
TGFβ1-mediated EMT-associated decreases in E-cadherin were
also reversed by 24 h co-incubation with GSI in HK-2 and RPTEC cells,1
DAM protease
-secretase
Nucleus
THBS1
CTGF
Grem1
on adjacent cell)
Cytosol
X
y epithelial cells. Activation of TGFβ receptors triggers activation of multiple pathways
involving Jagged/Delta ligands and Notch receptors on adjacent cells triggers ADAM-
of the Notch intracellular domain (NICD) which translocates to the nucleus and binds to
transcription. TGFβ1-responsive genes such as E-cadherin and Jagged1 require Notch
BS1), CTGF and Grem1 appear to be activated by TGFβ1 independent of Notch receptor
β1 targets such as Jagged1 (solid arrow) but not other genes such as E-cadherin (dashed
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associated with TGFβ-induced cytoskeletal changes in EMT such as α-
SMA were also sensitive to GSI at different concentrations (Fig. 3B, C;
Suppl. Fig. 3B). Clear changes in HK-2 cell phenotype were observed
with TGFβ1, with actin rearrangement, increased stress ﬁbres and a
more “ﬁbroblast”-like cell shape evident (Fig. 5). Increased staining
for α-SMA at the lamellopodial extrusions and decreased E-cadherin
staining at cell–cell junctions clearly suggested EMT-like changes in
these cells (Fig. 5). GSI treatment reversed these effects on α-SMA
expression, E-cadherin staining and overall “intermediate” cell
phenotype (Fig. 5). However, TGFβ-induced increases in genes not
involved in disassembly of adherens junctions such as CTGF, THBS1
and Grem1 were insensitive to inhibition by GSI (Fig. 3D–F). These
data suggest that Notch signalling may play a more pronounced role
in the regulation of a subset of TGFβ1-regulated genes involved in
EMT. Proteolytically cleaved Notch (NICD) shuttles to the nucleus
where it binds to CSL proteins, triggering transcriptional derepression
of CSL-targeted genes in a complex manner [19]. Indeed, over-
expression of NICD induced Jagged1 and α-SMA expression in HK-2
cells in the absence and presence of TGFβ1 (Fig. 6A, B; Suppl. Fig. 4).
The lack of robust changes in E-cadherin mRNA and protein levels in
cells transfected with NICD is surprising, and can possibly be
explained by NICD being necessary but not sufﬁcient for E-cadherin
transcriptional repression, but necessary and sufﬁcient for Jagged1
and α-SMA transcriptional activation. Transfection of RPMS1, a
negative regulator of Notch IC via binding to the CBF-1 co-repressor
complex [36], had minimal effects on gene expression minus/plus
TGFβ1 (Fig. 6). While transfection efﬁciency is likely to be an issue
here, the inability of RPMS-1 to abolish TGFβ1-mediated effects on
Jagged1, α-SMA and E-cadherin supports the concept that Notch
signalling is only one element of an intricate mechanism of TGFβ1-
mediated transcriptional regulation. Recent data reporting the role of
miRNA-192 in regulating TGFβ1-induced EMT and ﬁbrosis in DN
support a complex model of transcriptional regulation downstream of
TGFβ1 in renal epithelial cells [42].
Multiple downstream signal transduction pathways are activated
by TGFβ1, including canonical Smad signalling, PI3K, RhoA, NFκB and
MAPK (reviewed in [43]). TGFβ1-induced increases in Jagged1 were
completely Smad3 dependent and partially PI3K/MEK dependent
(Fig. 7). These data are consistent with previous observations
demonstrating that genetic deletion of Smad3 abolishes TGFβ1-
induced Hey1 and Jagged1 induction in primary mouse tubular
epithelial cells [27]. Bioinformatic analysis of the predicted Jagged1
promoter (3 kb upstream of the transcription start site) identiﬁed
Smad3/Smad4 binding sites in human, mouse and rat sequences
suggesting that direct regulation of Jagged1 transcription occurs via
Smad3/4 promoter binding (data not shown). Previous data from our
laboratory and others showed that TGFβ1-induced changes in EMT-
associated proteins such as E-cadherin andα-SMAwere also PI3K/Akt
dependent in kidney epithelial cells [5], as well asmammary epithelial
cells [4]. Previous authors have identiﬁed a crosstalk between Notch
signalling and Akt, where increased Akt activity in lymphoblasts leads
to resistance to GSI-mediated Notch inhibition and T-cell apoptosis
[44]. Additionally, Akt has been shown to directly interact with
Smad3 preventing its phosphorylation and nuclear accumulation and
inhibiting TGFβ1-induced apoptosis [45,46]. Thus, a complex se-
quence of signalling events and interactions involving Notch, Smad
proteins and PI3K/Akt mediate epithelial cell responses to TGFβ1.
The requirement for Jagged/Notch activity for TGFβ1-mediated
expression of Jagged1 and EMT-associated genes such as E-cadherin
suggests that these genes contain NICD/CSL target sequences in their
promoter regions. MatInspector analysis identiﬁed RBPJ (a compo-
nent of the CSL complex) transcription factor binding sites in both
human Jagged1 and Hes1, but not CTGF or THBS1. This site was not
predicted in human E-cadherin promoter, and only Hes1 contained
conserved RBPJ sites in human, mouse and rat promoters (data notshown). Others have demonstrated that Notch activation drives the
expression of transcription factors such as Snail and Slug which
directly regulate genes such as E-cadherin to induce EMT inmammary
and kidney epithelial cells [47,48]. We predict that TGFβ1 target genes
sensitive to GSI may contain CSL recognition sequences in their
promoters, compared to TGFβ1 target genes such as CTGF and THBS1
which may not contain these CSL sites. Future approaches using
bioinformatics and chromatin immunoprecipitation using NICD/CSL
antibodies will interrogate this hypothesis. Together with data from
other authors using different epithelial cells such as primary human
proximal tubule (PTEC), keratinocytes and primary human breast
epithelia our results suggest that Notch signalling may impinge on
speciﬁc gene responses involved in TGFβ-induced EMT [24,27,47,48].
Future experiments will elucidate the exact mechanisms of Notch-
mediated regulation of TGFβ1 gene transcription in epithelial cells.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2010.09.001.
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